Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SLIM: Shortened LSD Intervention for Major Depressive Disorder
NCT07503002Phase 1Not yet recruiting
- Sponsor
- Johns Hopkins University
- Start
- Dec 2026
- Primary completion
- Jul 2027
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Lysergide in major depressive disorder (MDD), sponsored by Johns Hopkins University. Primary endpoint: Montgomery Asberg Depression Rating Scale at 1 month. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
Lysergide
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT07503002.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07503002.